PFS. (A) PFS for the 49 patients responsive to CDP therapy. Blue bar indicates CDP treatment, and its length shows the time from first dosing until disease progression, relapse, or discontinuation of CDP treatment. Orange bar indicates treatment cessation, and its length shows the time from cessation until disease relapse. The onset time of first response (CR or PR) is indicated as a red circle (CR) or a blue square (PR), respectively. (B) Duration of response (DOR) for patients with the best response of CR vs PR after CDP therapy. Shown are median DOR and 2-year DOR rates (95% CI); long-rank (Mantel-Cox) test. (C) Overall PFS for the entire cohort. (D) PFS for patients who acquired CR vs PR vs SD/PD after CDP therapy. Shown are median PFS (mPFS) and 2-year PFS rates (95% CI); long-rank (Mantel-Cox) test. (E) PFS for patients based on the best response to prior DP treatment (CR/PR vs SD/PD). Shown are mPFS (95% CI), long-rank (Mantel-Cox) test. (F) PFS for the overall patients achieved from CDP therapy vs prior DP therapy. (G) Twenty-six patients previously received anti–PD-1 monotherapy (P), DP therapy, and subsequently were treated with CDP therapy in this study. PFS curves of prior P monotherapy, prior DP therapy, and CDP therapy for the 26 patients are shown. mPFS and 2-year PFS rates are shown. P value <.05 is considered significant.